Structure, function, regulation and polymorphism of human cytochrome P450 2A6

Current Drug Metabolism

Volumn 10, Issue 7, 2009, Pages 754-780

  Di, Yuan Ming ^a   Chow, Vivian Deh Wei ^a   Yang, Li Ping ^b   Zhou, Shu Feng ^a  

^a RMIT UNIVERSITY   (Australia)

^b BEIJING HOSPITAL   (China)

Author keywords

CYP2A6; Inhibitor; Nicotine; Nuclear receptor; Polymorphism

Indexed keywords

AFLATOXIN B1; CAFFEINE; CELL NUCLEUS RECEPTOR; CISAPRIDE; CLOMETHIAZOLE; COUMARIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2A6; DEXAMETHASONE; DISULFIRAM; FADROZOLE; FLUOROURACIL; IFOSFAMIDE; ISONIAZID; KETOCONAZOLE; LOSIGAMONE; METHOXSALEN; MIFEPRISTONE; NAPHTHALENE; NICOTINE; NITROSAMINE; ORPHENADRINE; PILOCARPINE; PROMAZINE; PROPOFOL; SELEGILINE; TAMOXIFEN; TEGAFUR; UNINDEXED DRUG; VALPROIC ACID;

BIOTRANSFORMATION; CANCER RISK; CHROMOSOME 9; CRYSTAL STRUCTURE; DEALKYLATION; DEMETHYLATION; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME RELEASE; ENZYME SPECIFICITY; EPOXIDATION; EXON; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE STRUCTURE; GENE TARGETING; HUMAN; HYDROGEN BOND; HYDROXYLATION; INTRON; LUNG CANCER; NONHUMAN; OXIDATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REGULATORY MECHANISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; SMOKING; SMOKING CESSATION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY;

EID: 72949119129     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009789895507     Document Type: Review

References (263)

1. Nebert, D. W.; Russell, D. W. Clinical importance of the cytochromes P450. Lancet, 2002, 360(9340), 1155-1162.
2. Guengerich, F. P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. Aaps J., 2006, 8(1), E101-111.
3. Ingelman-Sundberg, M.; Sim, S. C.; Gomez, A.; Rodriguez-Antona, C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther., 2007, 116(3), 496-526.
4. Zhou, S. F.; Di, Y. M.; Chan, E.; Du, Y. M.; Chow, V. D.; Xue, C. C.; Lai, X.; Wang, J. C.; Li, C. G.; Tian, M.; Duan, W. Clinical pharmacogenetics and potential application in personalized medicine. Curr. Drug Metab., 2008, 9(8), 738-784.
5. Zhou, S. F.; Liu, J. P.; Chowbay, B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev., 2009, 41(2), 89-295.
6. Kirchheiner, J.; Seeringer, A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim. Biophys. Acta, 2007, 1770(3), 489-494.
7. Hoffman, S. M.; Fernandez-Salguero, P.; Gonzalez, F. J.; Mohrenweiser, H. W. Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19. J. Mol. Evol., 1995, 41(6), 894-900.
8. Sheng, J.; Guo, J.; Hua, Z.; Caggana, M.; Ding, X. Characterization of human CYP2G genes: widespread loss-of-function mutations and genetic polymorphism. Pharmacogenetics, 2000, 10(8), 667-678.
9. Raunio, H.; Rautio, A.; Pelkonen, O. The CYP2A subfamily: function, expression and genetic polymorphism. IARC Sci. Publ., 1999, 148, 197-207.
10. Fernandez-Salguero, P.; Gonzalez, F. J. The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics, 1995, 5 (Spec No.) S123-128.
11. Miles, J. S.; Bickmore, W.; Brook, J. D.; McLaren, A. W.; Meehan, R.; Wolf, C. R. Close linkage of the human cytochrome P450IIA and P450IIB gene subfamilies: implications for the assignment of substrate specificity. Nucleic Acids Res., 1989, 17(8), 2907-2917.
12. Koskela, S.; Hakkola, J.; Hukkanen, J.; Pelkonen, O.; Sorri, M.; Saranen, A.; Anttila, S.; Fernandez-Salguero, P.; Gonzalez, F.; Raunio, H. Expression of CYP2A genes in human liver and extra-hepatic tissues. Biochem. Pharmacol., 1999, 57(12), 1407-1413.
13. Rendic, S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev., 2002, 34(1-2), 83-448.
14. Mahavorasirikul, W.; Tassaneeyakul, W.; Satarug, S.; Reungweerayut, R.; Na-Bangchang, C.; Na-Bangchang, K. CYP2A6 genotypes and coumarin-oxidation phenotypes in a Thai population and their relationship to tobacco smoking. Eur. J. Clin. Pharmacol., 2009, 65(4), 377-384.
15. Peamkrasatam, S.; Sriwatanakul, K.; Kiyotani, K.; Fujieda, M.; Yamazaki, H.; Kamataki, T.; Yoovathaworn, K. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. Drug Metab. Pharmacokinet., 2006, 21(6), 475-484.
16. Benowitz, N. L.; Swan, G. E.; Jacob, P., 3rd; Lessov-Schlaggar, C. N.; Tyndale, R. F. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin. Pharmacol. Ther., 2006, 80(5), 457-467.
17. Daigo, S.; Takahashi, Y.; Fujieda, M.; Ariyoshi, N.; Yamazaki, H.; Koizumi, W.; Tanabe, S.; Saigenji, K.; Nagayama, S.; Ikeda, K.; Nishioka, Y.; Kamataki, T. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics, 2002, 12(4), 299-306.
18. Yun, C. H.; Shimada, T.; Guengerich, F. P. Purification and characterization of human liver microsomal cytochrome P450 2A6. Mol. Pharmacol., 1991, 40(5), 679-685.
19. Li, Y.; Li, N. Y.; Sellers, E. M. Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes. Eur. J. Drug Metab. Pharmacokinet., 1997, 22(4), 295-304.
20. Soucek, P. Expression of cytochrome P450 2A6 in Escherichia coli: purification, spectral and catalytic characterization, and preparation of polyclonal antibodies. Arch. Biochem. Biophys., 1999, 370(2), 190-200.
21. Miles, J. S.; McLaren, A. W.; Forrester, L. M.; Glancey, M. J.; Lang, M. A.; Wolf, C. R. Identification of the human liver cytochrome P450 responsible for coumarin 7-hydroxylase activity. Biochem. J., 1990, 267(2), 365-371.
22. Nakajima, M.; Itoh, M.; Yamanaka, H.; Fukami, T.; Tokudome, S.; Yamamoto, Y.; Yamamoto, H.; Yokoi, T. Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6. J. Clin. Pharmacol., 2006, 46(3), 337-344.
23. Murphy, S. E.; Johnson, L. M.; Losey, L. M.; Carmella, S. G.; Hecht, S. S. Consumption of watercress fails to alter coumarin metabolism in humans. Drug Metab. Dispos., 2001, 29(6), 786-788.
24. Schlicht, K. E.; Michno, N.; Smith, B. D.; Scott, E. E.; Murphy, S. E. Functional characterization of CYP2A13 polymorphisms. Xenobiotica, 2007, 37(12), 1439-1449.
25. Kiyotani, K.; Yamazaki, H.; Fujieda, M.; Iwano, S.; Matsumura, K.; Satarug, S.; Ujjin, P.; Shimada, T.; Guengerich, F. P.; Parkinson, A.; Honda, G.; Nakagawa, K.; Ishizaki, T.; Kamataki, T. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics, 2003, 13(11), 689-695.
26. Kim, D.; Wu, Z. L.; Guengerich, F. P. Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis. J. Biol. Chem., 2005, 280(48), 40319-40327.
27. Lewis, D. F. Human cytochromes P450 associated with the Phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr. Med. Chem., 2003, 10(19), 1955-1972.
28. Zanger, U. M.; Klein, K.; Saussele, T.; Blievernicht, J.; Hofmann, M. H.; Schwab, M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics, 2007, 8(7), 743-759.
29. Sadeque, A. J.; Fisher, M. B.; Korzekwa, K. R.; Gonzalez, F. J.; Rettie, A. E. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J. Pharmacol. Exp. Ther., 1997, 283(2), 698-703.
30. Torchin, C. D.; McNeilly, P. J.; Kapetanovic, I. M.; Strong, J. M.; Kupferberg, H. J. Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes. Drug Metab. Dispos., 1996, 24(9), 1002-1008.
31. Spracklin, D. K.; Thummel, K. E.; Kharasch, E. D. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab. Dispos., 1996, 24(9), 976-983.
32. Madan, A.; Parkinson, A.; Faiman, M. D. Identification of the human P450 enzymes responsible for the sulfoxidation and thionooxidation of diethyldithiocarbamate methyl ester: role of P450 enzymes in disulfiram bioactivation. Alcohol Clin. Exp. Res., 1998, 22(6), 1212-1219.
33. Chang, T. K.; Weber, G. F.; Crespi, C. L.; Waxman, D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res., 1993, 53(23), 5629-5637.
34. Ikeda, K.; Yoshisue, K.; Matsushima, E.; Nagayama, S.; Kobayashi, K.; Tyson, C. A.; Chiba, K.; Kawaguchi, Y. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P450 2A6 in human liver microsomes in vitro. Clin. Cancer Res., 2000, 6(11), 4409-4415.
35. Komatsu, T.; Yamazaki, H.; Shimada, N.; Nakajima, M.; Yokoi, T. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab. Dispos., 2000, 28(12), 1457-1463.
36. Endo, T.; Ban, M.; Hirata, K.; Yamamoto, A.; Hara, Y.; Momose, Y. Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes. Drug Metab. Dispos., 2007, 35(3), 476-483.
37. Desta, Z.; Soukhova, N.; Morocho, A. M.; Flockhart, D. A. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A. J. Pharmacol. Exp. Ther., 2001, 298(2), 508-520.
38. Bohets, H.; Lavrijsen, K.; Hendrickx, J.; van Houdt, J.; van Genechten, V.; Verboven, P.; Meuldermans, W.; Heykants, J. Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br. J. Pharmacol., 2000, 129(8), 1655-1667.
39. Belliard, A. M.; Baune, B.; Fakhfakh, M.; Hocquemiller, R.; Farinotti, R. Determination of the human cytochrome P450s involved in the metabolism of 2n-propylquinoline. Xenobiotica, 2003, 33(4), 341-355.
40. Oscarson, M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab. Dispos., 2001, 29(2), 91-95.
41. Murphy, S. E.; Raulinaitis, V.; Brown, K. M. Nicotine 5′-oxidation and methyl oxidation by P450 2A enzymes. Drug Metab. Dispos., 2005, 33(8), 1166-1173.
42. Hecht, S. S.; Hochalter, J. B.; Villalta, P. W.; Murphy, S. E. 2′-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. Proc. Natl. Acad. Sci. USA, 2000, 97(23), 12493-12497.
43. Messina, E. S.; Tyndale, R. F.; Sellers, E. M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther., 1997, 282(3), 1608-1614.
44. Berkman, C. E.; Park, S. B.; Wrighton, S. A.; Cashman, J. R. In vitro-in vivo correlations of human S-nicotine metabolism. Biochem. Pharmacol., 1995, 50(4), 565-570.
45. Nakajima, M.; Yamamoto, T.; Nunoya, K.; Yokoi, T.; Nagashima, K.; Inoue, K.; Funae, Y.; Shimada, N.; Kamataki, T.; Kuroiwa, Y. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos., 1996, 24(11), 1212-1217.
46. Nakajima, M.; Yamamoto, T.; Nunoya, K.; Yokoi, T.; Nagashima, K.; Inoue, K.; Funae, Y.; Shimada, N.; Kamataki, T.; Kuroiwa, Y. Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther., 1996, 277(2), 1010-1015.
47. Dicke, K. E.; Skrlin, S. M.; Murphy, S. E. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab. Dispos., 2005, 33(12), 1760-1764.
48. Yamazaki, H.; Inoue, K.; Hashimoto, M.; Shimada, T. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch. Toxicol., 1999, 73(2), 65-70.
49. Dempsey, D.; Tutka, P.; Jacob, P., 3rd; Allen, F.; Schoedel, K.; Tyndale, R. F.; Benowitz, N. L. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther., 2004, 76(1), 64-72.
50. Yamanaka, H.; Nakajima, M.; Fukami, T.; Sakai, H.; Nakamura, A.; Katoh, M.; Takamiya, M.; Aoki, Y.; Yokoi, T. CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab. Dispos., 2005, 33(12), 1811-1818.
51. Brown, P. J.; Bedard, L. L.; Reid, K. R.; Petsikas, D.; Massey, T. E. Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone in human peripheral lung microsomes. Drug Metab. Dispos., 2007, 35(11), 2086-2094.
52. Duescher, R. J.; Elfarra, A. A. Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P450 2A6 and 2E1. Arch. Biochem. Biophys., 1994, 311(2), 342-349.
53. Le Gal, A.; Dreano, Y.; Lucas, D.; Berthou, F. Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine. Toxicol. Lett., 2003, 144(1), 77-91.
54. Liu, C.; Zhuo, X.; Gonzalez, F. J.; Ding, X. Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2A6: role in metabolic activation of nasal toxicants. Mol. Pharmacol., 1996, 50(4), 781-788.
55. Hong, J. Y.; Wang, Y. Y.; Bondoc, F. Y.; Lee, M.; Yang, C. S.; Hu, W. Y.; Pan, J. Metabolism of methyl tert-butyl ether and other gasoline ethers by human liver microsomes and heterologously expressed human cytochromes P450: identification of CYP2A6 as a major catalyst. Toxicol. Appl. Pharmacol., 1999, 160(1), 43-48.
56. Hong, J. Y.; Yang, C. S.; Lee, M.; Wang, Y. Y.; Huang, W. Q.; Tan, Y.; Patten, C. J.; Bondoc, F. Y. Role of cytochromes P450 in the metabolism of methyl tert-butyl ether in human livers. Arch. Toxicol., 1997, 71(4), 266-269.
57. Le Gal, A.; Dreano, Y.; Gervasi, P. G.; Berthou, F. Human cytochrome P450 2A6 is the major enzyme involved in the metabolism of three alkoxyethers used as oxyfuels. Toxicol. Lett., 2001, 124(1-3), 47-58.
58. Cho, T. M.; Rose, R. L.; Hodgson, E. In vitro metabolism of naphthalene by human liver microsomal cytochrome P450 enzymes. Drug Metab. Dispos., 2006, 34(1), 176-183.
59. Miyazawa, M.; Sugie, A.; Shimada, T. Roles of human CYP2A6 and 2B6 and rat CYP2C11 and 2B1 in the 10-hydroxylation of (-)-verbenone by liver microsomes. Drug Metab. Dispos., 2003, 31(8), 1049-1053.
60. Miyazawa, M.; Gyoubu, K. Roles of human CYP2A6 and rat CYP2B1 in the oxidation of (+)-fenchol by liver microsomes. Xenobiotica, 2007, 37(9), 943-953.
61. Miyazawa, M.; Gyoubu, K. Metabolism of (-)-fenchone by CYP2A6 and CYP2B6 in human liver microsomes. Xenobiotica, 2007, 37(2), 194-204.
62. Gyoubu, K.; Miyazawa, M. In vitro metabolism of (-)-camphor using human liver microsomes and CYP2A6. Biol. Pharm. Bull., 2007, 30(2), 230-233.
63. Liu, H. X.; Hu, Y.; Liu, Y.; He, Y. Q.; Li, W.; Yang, L. Hydroxylation of tanshinone IIa in human liver microsomes is specifically catalysed by cytochrome P4502A6. Xenobiotica, 2009, 39(5), 382-390.
64. McSorley, L. C.; Daly, A. K. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem. Pharmacol., 2000, 60(4), 517-526.
65. Marill, J.; Cresteil, T.; Lanotte, M.; Chabot, G. G. Identification of human cytochrome P450s involved in the formation of all-transretinoic acid principal metabolites. Mol. Pharmacol., 2000, 58(6), 1341-1348.
66. Yamazaki, H.; Mimura, M.; Sugahara, C.; Shimada, T. Catalytic roles of rat and human cytochrome P450 2A enzymes in testosterone 7α- and coumarin 7-hydroxylations. Biochem. Pharmacol., 1994, 48(7), 1524-1527.
67. Lee, A. J.; Cai, M. X.; Thomas, P. E.; Conney, A. H.; Zhu, B. T. Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms. Endocrinology, 2003, 144(8), 3382-3398.
68. Lee, A. J.; Kosh, J. W.; Conney, A. H.; Zhu, B. T. Characterization of the NADPH-dependent metabolism of 17β-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5. J. Pharmacol. Exp. Ther., 2001, 298(2), 420-432.
69. Niwa, T.; Yabusaki, Y.; Honma, K.; Matsuo, N.; Tatsuta, K.; Ishibashi, F.; Katagiri, M. Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica, 1998, 28(6), 539-547.
70. Nakajima, M.; Itoh, M.; Sakai, H.; Fukami, T.; Katoh, M.; Yamazaki, H.; Kadlubar, F. F.; Imaoka, S.; Funae, Y.; Yokoi, T. CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. Int. J. Cancer, 2006, 119(11), 2520-2526.
71. Siu, E. C.; Tyndale, R. F. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J. Pharmacol. Exp. Ther., 2008, 324(3), 992-999.
72. Wen, X.; Wang, J. S.; Kivisto, K. T.; Neuvonen, P. J.; Backman, J. T. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br. J. Clin. Pharmacol., 2001, 52(5), 547-553.
73. Wen, X.; Wang, J. S.; Neuvonen, P. J.; Backman, J. T. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol., 2002, 57(11), 799-804.
74. Koenigs, L. L.; Trager, W. F. Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochemistry, 1998, 37(28), 10047-10061.
75. Draper, A. J.; Madan, A.; Parkinson, A. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch. Biochem. Biophys., 1997, 341(1), 47-61.
76. Khojasteh-Bakht, S. C.; Koenigs, L. L.; Peter, R. M.; Trager, W. F.; Nelson, S. D. (R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab. Dispos., 1998, 26(7), 701-704.
77. Yoo, H. H.; Lee, M. W.; Kim, Y. C.; Yun, C. H.; Kim, D. H. Mechanism-based inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica Gigas. Drug Metab. Dispos., 2007, 35(10), 1759-1765.
78. Koenigs, L. L.; Peter, R. M.; Thompson, S. J.; Rettie, A. E.; Trager, W. F. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab. Dispos., 1997, 25(12), 1407-1415.
79. Xia, X. Y.; Peng, R. X.; Yu, J. P.; Wang, H.; Wang, J. In vitro metabolic characteristics of cytochrome P450 2A6 in Chinese liver microsomes. Acta Pharmacol. Sin., 2002, 23(5), 471-476.
80. Bourrie, M.; Meunier, V.; Berger, Y.; Fabre, G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther., 1996, 277(1), 321-332.
81. Kinonen, T.; Pasanen, M.; Gynther, J.; Poso, A.; Jarvinen, T.; Alhava, E.; Juvonen, R. O. Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP 2A5 and human CYP 2A6. Br. J. Pharmacol., 1995, 116(6), 2625-2630.
82. Kimonen, T.; Juvonen, R. O.; Alhava, E.; Pasanen, M. The inhibition of CYP enzymes in mouse and human liver by pilocarpine. Br. J. Pharmacol., 1995, 114(4), 832-836.
83. Taavitsainen, P.; Juvonen, R.; Pelkonen, O. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab. Dispos., 2001, 29(3), 217-222.
84. Sellers, E. M.; Kaplan, H. L.; Tyndale, R. F. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin. Pharmacol. Ther., 2000, 68(1), 35-43.
85. Guo, Z.; Raeissi, S.; White, R. B.; Stevens, J. C. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab. Dispos., 1997, 25(3), 390-393.
86. Franklin, M. R.; Hathaway, L. B. 2-Diethylaminoethyl-2,2- diphenylvalerate-HCl (SKF525A) revisited: comparative cytochrome P450 inhibition in human liver microsomes by SKF525A, its metabolites, and SKF-acid and SKF-alcohol. Drug Metab. Dispos., 2008, 36(12), 2539-2546.
87. Nakajima, M.; Yoshida, R.; Shimada, N.; Yamazaki, H.; Yokoi, T. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab. Dispos., 2001, 29(8), 1110-1113.
88. von Weymarn, L. B.; Chun, J. A.; Knudsen, G. A.; Hollenberg, P. F. Effects of eleven isothiocyanates on P450 2A6- and 2A13-catalyzed coumarin 7-hydroxylation. Chem. Res. Toxicol., 2007, 20(9), 1252-1259.
89. Fujita, K.; Kamataki, T. Screening of organosulfur compounds as inhibitors of human CYP2A6. Drug Metab. Dispos., 2001, 29(7), 983-989.
90. Higashi, E.; Nakajima, M.; Katoh, M.; Tokudome, S.; Yokoi, T. Inhibitory effects of neurotransmitters and steroids on human CYP2A6. Drug Metab. Dispos., 2007, 35(4), 508-514.
91. Maenpaa, J.; Juvonen, R.; Raunio, H.; Rautio, A.; Pelkonen, O. Metabolic interactions of methoxsalen and coumarin in humans and mice. Biochem. Pharmacol., 1994, 48(7), 1363-1369.
92. Kharasch, E. D.; Hankins, D. C.; Taraday, J. K. Single-dose methoxsalen effects on human cytochrome P450 2A6 activity. Drug Metab. Dispos., 2000, 28(1), 28-33.
93. Yew, W. W. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf., 2002, 25(2), 111-133.
94. Kutt, H.; Verebely, K.; McDowell, F. Inhibition of diphenylhydantoin metabolism in rats and in rat liver microsomes by antitubercular drugs. Neurology, 1968, 18(7), 706-710.
95. Miller, R. R.; Porter, J.; Greenblatt, D. J. Clinical importance of the interaction of phenytoin and isoniazid: a report from the Boston Collaborative Drug Surveillance Program. Chest, 1979, 75(3), 356-358.
96. Höglund, P.; Nilsson, L. G.; Paulsen, O. Interaction between isoniazid and theophylline. Eur. J. Respir. Dis., 1987, 70(2), 110-116.
97. Samigun; Mulyono; Santoso, B. Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. Br. J. Clin. Pharmacol., 1990, 29(5), 570-573.
98. Ochs, H. R.; Greenblatt, D. J.; Roberts, G. M.; Dengler, H. J. Diazepam interaction with antituberculosis drugs. Clin. Pharmacol. Ther., 1981, 29(5), 671-678.
99. Grech-Belanger, O.; Belanger, P. M.; Lachance, J. Inhibitory effect of isoniazid on antipyrine clearance in man. J. Clin. Pharmacol., 1983, 23(11-12), 540-544.
100. Ochs, H. R.; Greenblatt, D. J.; Knuchel, M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. Br. J. Clin. Pharmacol., 1983, 16(6), 743-746.
101. Zand, R.; Nelson, S. D.; Slattery, J. T.; Thummel, K. E.; Kalhorn, T. F.; Adams, S. P.; Wright, J. M. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin. Pharmacol. Ther., 1993, 54(2), 142-149.
102. Chien, J. Y.; Peter, R. M.; Nolan, C. M.; Wartell, C.; Slattery, J. T.; Nelson, S. D.; Carithers, R. L. J. r.; Thummel, K. E. Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid. Clin. Pharmacol. Ther., 1997, 61(1), 24-34.
103. Crippin, J. S. Acetaminophen hepatotoxicity: potentiation by isoniazid. Am. J. Gastroenterol., 1993, 88(4), 590-595.
104. O'Shea, D.; Kim, R. B.; Wilkinson, G. R. Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. Br. J. Clin. Pharmacol., 1997, 43(1), 99-103.
105. Wright, J. M.; Stokes, E. F.; Sweeney, V. P. Isoniazid-induced carbamazepine toxicity and vice versa: a double drug interaction. N. Engl. J. Med., 1982, 307(21), 1325-1327.
106. Valsalan, V. C.; Cooper, G. L. Carbamazepine intoxication caused by interaction with isoniazid. Br. Med. J., 1982, 285(6337), 261-262.
107. Wright, J. M. Carbamazepine-isoniazid interaction. Pediatrics, 1983, 71(1), 139.
108. Chan, J. D. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy, 1998, 18(6), 1304-1307.
109. Sutton, G.; Kupferberg, H. J. Isoniazid as an inhibitor of primidone metabolism. Neurology, 1975, 25(12), 1179-1181.
110. Whittington, H. G.; Grey, L. Possible interaction between disulfiram and isoniazid. Am. J. Psychiatry, 1969, 125(12), 1725-1729.
111. Zhou, S. F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab., 2008, 9(4), 310-322.
112. Yano, J. K.; Hsu, M. H.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat. Struct. Mol. Biol., 2005, 12(9), 822-823.
113. Ravichandran, K. G.; Boddupalli, S. S.; Hasermann, C. A.; Peterson, J. A.; Deisenhofer, J. Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. Science, 1993, 261(5122), 731-736.
114. Poso, A.; Juvonen, R.; Gynther, J. Comparative molecular field analysis of compounds with CYP2A5 binding affinity. Quant. Struct. Act. Relat., 1995, 14(6), 507-511.
115. Bravi, G.; Wikel, J. H. Application of MS-WHIM Descriptors 1. Introduction of new molecular surface properties and 2. Prediction of binding affinity data. Quant. Struct. Act. Relat., 2000, 19(1), 29-38.
116. Lewis, D. F.; Dickins, M.; Lake, B. G.; Eddershaw, P. J.; Tarbit, M. H.; Goldfarb, P. S. Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity. Toxicology, 1999, 133(1), 1-33.
117. Poso, A.; Gynther, J.; Juvonen, R. A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors. J. Comput. Aided Mol. Des., 2001, 15(3), 195-202.
118. Rahnasto, M.; Raunio, H.; Poso, A.; Wittekindt, C.; Juvonen, R. O. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J. Med. Chem., 2005, 48(2), 440-449.
119. Lewis, D. F.; Lake, B. G.; Dickins, M.; Goldfarb, P. S. Homology modelling of CYP2A6 based on the CYP2C5 crystallographic template: enzyme-substrate interactions and QSARs for binding affinity and inhibition. Toxicol. In Vitro, 2003, 17(2), 179-190.
120. Lewis, D. F. Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch. Biochem. Biophys., 2003, 409(1), 32-44.
121. Williams, P. A.; Cosme, J.; Sridhar, V.; Johnson, E. F.; McRee, D. E. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell, 2000, 5(1), 121-131.
122. Yamano, S.; Tatsuno, J.; Gonzalez, F. J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry, 1990, 29(5), 1322-1329.
123. Hadidi, H.; Zahlsen, K.; Idle, J. R.; Cholerton, S. A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food. Chem. Toxicol., 1997, 35(9), 903-907.
124. Nakamura, K.; Martin, M. V.; Guengerich, F. P. Random mutagenesis of human cytochrome P450 2A6 and screening with indole oxidation products. Arch. Biochem. Biophys., 2001, 395(1), 25-31.
125. He, X. Y.; Shen, J.; Hu, W. Y.; Ding, X.; Lu, A. Y.; Hong, J. Y. Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation. Arch. Biochem. Biophys., 2004, 427(2), 143-153.
126. Wu, Z. L.; Podust, L. M.; Guengerich, F. P. Expansion of substrate specificity of cytochrome P450 2A6 by random and site-directed mutagenesis. J. Biol. Chem., 2005, 280(49), 41090-41100.
127. Kim, D.; Guengerich, F. P. Enhancement of 7-methoxyresorufin O-demethylation activity of human cytochrome P450 1A2 by molecular breeding. Arch. Biochem. Biophys., 2004, 432(1), 102-108.
128. DeVore, N. M.; Smith, B. D.; Wang, J. L.; Lushington, G. H.; Scott, E. E. Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes. Drug Metab. Dispos., 2009, 37(6), 1319-1327.
129. Yano, J. K.; Denton, T. T.; Cerny, M. A.; Zhang, X.; Johnson, E. F.; Cashman, J. R. Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J. Med. Chem., 2006, 49(24), 6987-7001.
130. Sansen, S.; Hsu, M. H.; Stout, C. D.; Johnson, E. F. Structural insight into the altered substrate specificity of human cytochrome P450 2A6 mutants. Arch. Biochem. Biophys., 2007, 464(2), 197-206.
131. Porubsky, P. R.; Meneely, K. M.; Scott, E. E. Structures of human cytochrome P450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. J. Biol. Chem., 2008, 283(48), 33698-33707.
132. Wortham, M.; Czerwinski, M.; He, L.; Parkinson, A.; Wan, Y. J. Expression of constitutive androstane receptor, hepatic nuclear factor 4α, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab. Dispos., 2007, 35(9), 1700-1710.
133. Itoh, M.; Nakajima, M.; Higashi, E.; Yoshida, R.; Nagata, K.; Yamazoe, Y.; Yokoi, T. Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-γ coactivator 1α. J. Pharmacol. Exp. Ther., 2006, 319(2), 693-702.
134. Onica, T.; Nichols, K.; Larin, M.; Ng, L.; Maslen, A.; Dvorak, Z.; Pascussi, J. M.; Vilarem, M. J.; Maurel, P.; Kirby, G. M. Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4α to the proximal promoter. Mol. Pharmacol., 2008, 73(2), 451-460.
135. Yokomori, N.; Nishio, K.; Aida, K.; Negishi, M. Transcriptional regulation by HNF-4 of the steroid 15α-hydroxylase P450 (Cyp2a4) gene in mouse liver. J. Steroid Biochem. Mol. Biol., 1997, 62(4), 307-314.
136. Ulvila, J.; Arpiainen, S.; Pelkonen, O.; Aida, K.; Sueyoshi, T.; Negishi, M.; Hakkola, J. Regulation of Cyp2a5 transcription in mouse primary hepatocytes: roles of hepatocyte nuclear factor 4 and nuclear factor I. Biochem. J., 2004, 381(Pt 3), 887-894.
137. Abu-Bakar, A.; Lamsa, V.; Arpiainen, S.; Moore, M. R.; Lang, M. A.; Hakkola, J. Regulation of CYP2A5 gene by the transcription factor nuclear factor (erythroid-derived 2)-like 2. Drug Metab. Dispos., 2007, 35(5), 787-794.
138. Jover, R.; Bort, R.; Gomez-Lechon, M. J.; Castell, J. V. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology, 2001, 33(3), 668-675.
139. Wang, J.; Pitarque, M.; Ingelman-Sundberg, M. 3′-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochem. Biophys. Res. Commun., 2006, 340(2), 491-497.
140. Madan, A.; Graham, R. A.; Carroll, K. M.; Mudra, D. R.; Burton, L. A.; Krueger, L. A.; Downey, A. D.; Czerwinski, M.; Forster, J.; Ribadeneira, M. D.; Gan, L. S.; LeCluyse, E. L.; Zech, K.; Robertson, P. J. r.; Koch, P.; Antonian, L.; Wagner, G.; Yu, L.; Parkinson, A. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos., 2003, 31(4), 421-431.
141. Dalet-Beluche, I.; Boulenc, X.; Fabre, G.; Maurel, P.; Bonfils, C. Purification of two cytochrome P450 isozymes related to CYP2A and CYP3A gene families from monkey (baboon, Papio papio) liver microsomes. Cross reactivity with human forms. Eur. J. Biochem., 1992, 204(2), 641-648.
142. Donato, M. T.; Viitala, P.; Rodriguez-Antona, C.; Lindfors, A.; Castell, J. V.; Raunio, H.; Gomez-Lechon, M. J.; Pelkonen, O. CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug Metab. Dispos., 2000, 28(11), 1321-1326.
143. Edwards, R. J.; Price, R. J.; Watts, P. S.; Renwick, A. B.; Tredger, J. M.; Boobis, A. R.; Lake, B. G. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab. Dispos., 2003, 31(3), 282-288.
144. Sotaniemi, E. A.; Rautio, A.; Backstrom, M.; Arvela, P.; Pelkonen, O. CYP3A4 and CYP2A6 activities marked by the metabolism of lignocaine and coumarin in patients with liver and kidney diseases and epileptic patients. Br. J. Clin. Pharmacol., 1995, 39(1), 71-76.
145. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. J. Pharmacol. Exp. Ther., 1994, 270(1), 414-423.
146. Hadidi, H.; Irshaid, Y.; Vagbo, C. B.; Brunsvik, A.; Cholerton, S.; Zahlsen, K.; Idle, J. R. Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6. Eur. J. Clin. Pharmacol., 1998, 54(5), 437-441.
147. Iscan, M.; Rostami, H.; Iscan, M.; Guray, T.; Pelkonen, O.; Rautio, A. Interindividual variability of coumarin 7-hydroxylation in a Turkish population. Eur. J. Clin. Pharmacol., 1994, 47(4), 315-318.
148. Rautio, A.; Kraul, H.; Kojo, A.; Salmela, E.; Pelkonen, O. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics, 1992, 2(5), 227-233.
149. Pasanen, M.; Rannala, Z.; Tooming, A.; Sotaniemi, E. A.; Pelkonen, O.; Rautio, A. Hepatitis A impairs the function of human hepatic CYP2A6 in vivo. Toxicology, 1997, 123(3), 177-184.
150. Shimada, T.; Yamazaki, H.; Guengerich, F. P. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica, 1996, 26(4), 395-403.
151. rd. Ethnic differences in N-glucuronidation of nicotine and cotinine. J. Pharmacol. Exp. Ther., 1999, 291(3), 1196-1203.
152. Fernandez-Salguero, P.; Hoffman, S. M.; Cholerton, S.; Mohrenweiser, H.; Raunio, H.; Rautio, A.; Pelkonen, O.; Huang, J. D.; Evans, W. E.; Idle, J. R.; et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am. J. Hum. Genet., 1995, 57(3), 651-660.
153. Zhuo, X.; Gu, J.; Zhang, Q. Y.; Spink, D. C.; Kaminsky, L. S.; Ding, X. Biotransformation of coumarin by rodent and human cytochromes P450: metabolic basis of tissue-selective toxicity in olfactory mucosa of rats and mice. J. Pharmacol. Exp. Ther., 1999, 288(2), 463-471.
154. Inoue, K.; Yamazaki, H.; Shimada, T. CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians. Arch. Toxicol., 2000, 73(10-11), 532-539.
155. Oscarson, M.; Gullsten, H.; Rautio, A.; Bernal, M. L.; Sinues, B.; Dahl, M. L.; Stengard, J. H.; Pelkonen, O.; Raunio, H.; Ingelman-Sundberg, M. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett., 1998, 438(3), 201-205.
156. Oscarson, M.; McLellan, R. A.; Gullsten, H.; Agundez, J. A.; Benitez, J.; Rautio, A.; Raunio, H.; Pelkonen, O.; Ingelman-Sundberg, M. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett., 1999, 460(2), 321-327.
157. Gaedigk, A.; Blum, M.; Gaedigk, R.; Eichelbaum, M.; Meyer, U. A. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/ sparteine polymorphism. Am. J. Hum. Genet., 1991, 48(5), 943-950.
158. Schoedel, K. A.; Hoffmann, E. B.; Rao, Y.; Sellers, E. M.; Tyndale, R. F. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics, 2004, 14(9), 615-626.
159. Oscarson, M.; McLellan, R. A.; Gullsten, H.; Yue, Q. Y.; Lang, M. A.; Bernal, M. L.; Sinues, B.; Hirvonen, A.; Raunio, H.; Pelkonen, O.; Ingelman-Sundberg, M. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett., 1999, 448(1), 105-110.
160. Chen, G. F.; Tang, Y. M.; Green, B.; Lin, D. X.; Guengerich, F. P.; Daly, A. K.; Caporaso, N. E.; Kadlubar, F. F. Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. Pharmacogenetics, 1999, 9(3), 327-332.
161. Nunoya, K.; Yokoi, T.; Kimura, K.; Inoue, K.; Kodama, T.; Funayama, M.; Nagashima, K.; Funae, Y.; Green, C.; Kinoshita, M.; Kamataki, T. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5- dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics, 1998, 8(3), 239-249.
162. Nunoya, K.; Yokoi, T.; Takahashi, Y.; Kimura, K.; Kinoshita, M.; Kamataki, T. Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype. J. Biochem., 1999, 126(2), 402-407.
163. Rao, Y.; Hoffmann, E.; Zia, M.; Bodin, L.; Zeman, M.; Sellers, E. M.; Tyndale, R. F. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol. Pharmacol., 2000, 58(4), 747-755.
164. Nakajima, M.; Kwon, J. T.; Tanaka, N.; Zenta, T.; Yamamoto, Y.; Yamamoto, H.; Yamazaki, H.; Yamamoto, T.; Kuroiwa, Y.; Yokoi, T. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clin. Pharmacol. Ther., 2001, 69(1), 72-78.
165. Kitagawa, K.; Kunugita, N.; Kitagawa, M.; Kawamoto, T. CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J. Biol. Chem., 2001, 276(21), 17830-17835.
166. Ariyoshi, N.; Sawamura, Y.; Kamataki, T. A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem. Biophys. Res. Commun., 2001, 281(3), 810-814.
167. Fukami, T.; Nakajima, M.; Higashi, E.; Yamanaka, H.; Sakai, H.; McLeod, H. L.; Yokoi, T. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug Metab. Dispos., 2005, 33(8), 1202-1210.
168. Yoshida, R.; Nakajima, M.; Watanabe, Y.; Kwon, J. T.; Yokoi, T. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br. J. Clin. Pharmacol., 2002, 54(5), 511-517.
169. Pitarque, M.; von Richter, O.; Oke, B.; Berkkan, H.; Oscarson, M.; Ingelman-Sundberg, M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun., 2001, 284(2), 455-460.
170. von Richter, O.; Pitarque, M.; Rodriguez-Antona, C.; Testa, A.; Mantovani, R.; Oscarson, M.; Ingelman-Sundberg, M. Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). Pharmacogenetics, 2004, 14(6), 369-379.
171. Xu, C.; Rao, Y. S.; Xu, B.; Hoffmann, E.; Jones, J.; Sellers, E. M.; Tyndale, R. F. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem. Biophys. Res. Commun., 2002, 290(1), 318-324.
172. Oscarson, M.; McLellan, R. A.; Asp, V.; Ledesma, M.; Bernal Ruiz, M. L.; Sinues, B.; Rautio, A.; Ingelman-Sundberg, M. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum. Mutat., 2002, 20(4), 275-283.
173. Kiyotani, K.; Fujieda, M.; Yamazaki, H.; Shimada, T.; Guengerich, F. P.; Parkinson, A.; Nakagawa, K.; Ishizaki, T.; Kamataki, T. Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians. Drug Metab. Pharmacokinet., 2002, 17(5), 482-487.
174. Fukami, T.; Nakajima, M.; Yoshida, R.; Tsuchiya, Y.; Fujiki, Y.; Katoh, M.; McLeod, H. L.; Yokoi, T. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin. Pharmacol. Ther., 2004, 76(6), 519-527.
175. Fukami, T.; Nakajima, M.; Higashi, E.; Yamanaka, H.; McLeod, H. L.; Yokoi, T. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Biochem. Pharmacol., 2005, 70(5), 801-808.
176. Haberl, M.; Anwald, B.; Klein, K.; Weil, R.; Fuss, C.; Gepdiremen, A.; Zanger, U. M.; Meyer, U. A.; Wojnowski, L. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet. Genomics, 2005, 15(9), 609-624.
177. Al Koudsi, N.; Mwenifumbo, J. C.; Sellers, E. M.; Benowitz, N. L.; Swan, G. E.; Tyndale, R. F. Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. Eur. J. Clin. Pharmacol., 2006, 62(6), 481-484.
178. Fukami, T.; Nakajima, M.; Yamanaka, H.; Fukushima, Y.; McLeod, H. L.; Yokoi, T. A novel duplication type of CYP2A6 gene in African-American population. Drug Metab. Dispos., 2007, 35(4), 515-520.
179. Fujieda, M.; Yamazaki, H.; Saito, T.; Kiyotani, K.; Gyamfi, M. A.; Sakurai, M.; Dosaka-Akita, H.; Sawamura, Y.; Yokota, J.; Kunitoh, H.; Kamataki, T. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis, 2004, 25(12), 2451-2458.
180. Yoshida, R.; Nakajima, M.; Nishimura, K.; Tokudome, S.; Kwon, J. T.; Yokoi, T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin. Pharmacol. Ther., 2003, 74(1), 69-76.
181. Kalow, W.; Tang, B. K. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin. Pharmacol. Ther., 1991, 49(1), 44-48.
182. Tassaneeyakul, W.; Mohamed, Z.; Birkett, D. J.; McManus, M. E.; Veronese, M. E.; Tukey, R. H.; Quattrochi, L. C.; Gonzalez, F. J.; Miners, J. O. Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics, 1992, 2(4), 173-183.
183. Carrillo, J. A.; Christensen, M.; Ramos, S. I.; Alm, C.; Dahl, M. L.; Benitez, J.; Bertilsson, L. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther. Drug Monit., 2000, 22(4), 409-417.
184. Tassaneeyakul, W.; Birkett, D. J.; McManus, M. E.; Tassaneeyakul, W.; Veronese, M. E.; Andersson, T.; Tukey, R. H.; Miners, J. O. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem. Pharmacol., 1994, 47(10), 1767-1776.
185. Ryu, J. Y.; Song, I. S.; Sunwoo, Y. E.; Shon, J. H.; Liu, K. H.; Cha, I. J.; Shin, J. G. Development of the "Inje cocktail" for highthroughput evaluation of five human cytochrome P450 isoforms in vivo. Clin. Pharmacol. Ther., 2007, 82(5), 531-540.
186. Kalow, W.; Tang, B. K. The use of caffeine for enzyme assays: a critical appraisal. Clin. Pharmacol. Ther., 1993, 53(5), 503-514.
187. Gu, L.; Gonzalez, F. J.; Kalow, W.; Tang, B. K. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics, 1992, 2(2), 73-77.
188. Kimura, M.; Yamazaki, H.; Fujieda, M.; Kiyotani, K.; Honda, G.; Saruwatari, J.; Nakagawa, K.; Ishizaki, T.; Kamataki, T. CYP2A6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab. Dispos., 2005, 33(9), 1361-1366.
189. Saruwatari, J.; Nakagawa, K.; Shindo, J.; Tajiri, T.; Fujieda, M.; Yamazaki, H.; Kamataki, T.; Ishizaki, T. A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. Clin. Pharmacol. Ther., 2002, 72(2), 200-208.
190. Benowitz, N. L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin. Pharmacol. Ther., 2008, 83(4), 531-541.
191. Kitagawa, K.; Kunugita, N.; Katoh, T.; Yang, M.; Kawamoto, T. The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. Biochem. Biophys. Res. Commun., 1999, 262(1), 146-151.
192. Pianezza, M. L.; Sellers, E. M.; Tyndale, R. F. Nicotine metabolism defect reduces smoking. Nature, 1998, 393(6687), 750.
193. Kubota, T.; Nakajima-Taniguchi, C.; Fukuda, T.; Funamoto, M.; Maeda, M.; Tange, E.; Ueki, R.; Kawashima, K.; Hara, H.; Fujio, Y.; Azuma, J. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. Pharmacogenomics J., 2006, 6(2), 115-119.
194. Endo, T.; Nakajima, M.; Fukami, T.; Hara, Y.; Hasunuma, T.; Yokoi, T.; Momose, Y. Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine. Pharmacogenet. Genomics, 2008, 18(9), 761-772.
195. Fujita, K.; Yamamoto, W.; Endo, S.; Endo, H.; Nagashima, F.; Ichikawa, W.; Tanaka, R.; Miya, T.; Araki, K.; Kodama, K.; Sunakawa, Y.; Narabayashi, M.; Miwa, K.; Ando, Y.; Akiyama, Y.; Kawara, K.; Kamataki, T.; Sasaki, Y. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci., 2008, 99(5), 1049-1054.
196. Nunoya, K.; Yokoi, Y.; Kimura, K.; Kodama, T.; Funayama, M.; Inoue, K.; Nagashima, K.; Funae, Y.; Shimada, N.; Green, C.; Kamataki, T. (+)-cis-3,5-Dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes. J. Pharmacol. Exp. Ther., 1996, 277(2), 768-774.
197. Nunoya, K. I.; Yokoi, T.; Kimura, K.; Kainuma, T.; Satoh, K.; Kinoshita, M.; Kamataki, T. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride in humans. J. Pharmacol. Exp. Ther., 1999, 289(1), 437-442.
198. Miyamoto, M.; Umetsu, Y.; Dosaka-Akita, H.; Sawamura, Y.; Yokota, J.; Kunitoh, H.; Nemoto, N.; Sato, K.; Ariyoshi, N.; Kamataki, T. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem. Biophys. Res. Commun., 1999, 261(3), 658-660.
199. Tan, W.; Chen, G. F.; Xing, D. Y.; Song, C. Y.; Kadlubar, F. F.; Lin, D. X. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int. J. Cancer, 2001, 95(2), 96-101.
200. Loriot, M. A.; Rebuissou, S.; Oscarson, M.; Cenee, S.; Miyamoto, M.; Ariyoshi, N.; Kamataki, T.; Hemon, D.; Beaune, P.; Stucker, I. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics, 2001, 11(1), 39-44.
201. Heller, T.; Kirchheiner, J.; Armstrong, V. W.; Luthe, H.; Tzvetkov, M.; Brockmoller, J.; Oellerich, M. AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther. Drug Monit., 2006, 28(5), 673-677.
202. Hinson, J. A.; Pumford, N. R.; Roberts, D. W. Mechanisms of acetaminophen toxicity: immunochemical detection of drug-protein adducts. Drug Metab. Rev., 1995, 27(1-2), 72-92.
203. Potter, W. Z.; Davis, D. C.; Mitchell, J. R.; Jollow, D. J.; Gillette, J. R.; Brodie, B. B. Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. J. Pharmacol. Exp. Ther., 1973, 187(1), 203-210.
204. Zhou, L.; Erickson, R. R.; Hardwick, J. P.; Park, S. S.; Wrighton, S. A.; Holtzman, J. L. Catalysis of the cysteine conjugation and protein binding of acetaminophen by microsomes from a human lymphoblast line transfected with the cDNAs of various forms of human cytochrome P450. J. Pharmacol. Exp. Ther., 1997, 281(2), 785-790.
205. Manyike, P. T.; Kharasch, E. D.; Kalhorn, T. F.; Slattery, J. T. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin. Pharmacol. Ther., 2000, 67(3), 275-282.
206. Agundez, J. A.; Martinez, C.; Benitez, J. Metabolism of aminopyrine and derivatives in man: in vivo study of monomorphic and polymorphic metabolic pathways. Xenobiotica, 1995, 25(4), 417-427.
207. Niwa, T.; Sato, R.; Yabusaki, Y.; Ishibashi, F.; Katagiri, M. Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica, 1999, 29(2), 187-193.
208. Brandon, E. F.; Sparidans, R. W.; van Ooijen, R. D.; Meijerman, I.; Lazaro, L. L.; Manzanares, I.; Beijnen, J. H.; Schellens, J. H. In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest. New Drugs, 2007, 25(1), 9-19.
209. Grace, J. M.; Skanchy, D. J.; Aguilar, A. J. Metabolism of artelinic acid to dihydroqinqhaosu by human liver cytochrome P4503A. Xenobiotica, 1999, 29(7), 703-717.
210. Gorski, J. C.; Jones, D. R.; Wrighton, S. A.; Hall, S. D. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica, 1997, 27(3), 243-256.
211. Kariya, S.; Isozaki, S.; Uchino, K.; Suzuki, T.; Narimatsu, S. Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol. Pharm. Bull., 1996, 19(11), 1511-1514.
212. Narimatsu, S.; Kariya, S.; Isozaki, S.; Ohmori, S.; Kitada, M.; Hosokawa, S.; Masubuchi, Y.; Suzuki, T. Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes. Biochem. Biophys. Res. Commun., 1993, 193(3), 1262-1268.
213. Desta, Z.; Soukhova, N.; Mahal, S. K.; Flockhart, D. A. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab. Dispos., 2000, 28(7), 789-800.
214. Rodrigues, A. D.; Roberts, E. M.; Mulford, D. J.; Yao, Y.; Ouellet, D. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab. Dispos., 1997, 25(5), 623-630.
215. Gebhardt, A. C.; Lucas, D.; Menez, J. F.; Seitz, H. K. Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology, 1997, 26(4), 957-961.
216. Hidestrand, M.; Oscarson, M.; Salonen, J. S.; Nyman, L.; Pelkonen, O.; Turpeinen, M.; Ingelman-Sundberg, M. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab. Dispos., 2001, 29(11), 1480-1484.
217. Madan, A.; Faiman, M. D. Characterization of diethyldithiocarbamate methyl ester sulfine as an intermediate in the bioactivation of disulfiram. J. Pharmacol. Exp. Ther., 1995, 272(2), 775-780.
218. Pike, M. G.; Mays, D. C.; Macomber, D. W.; Lipsky, J. J. Metabolism of a disulfiram metabolite, S-methyl N,N-diethyldithiocarbamate, by flavin monooxygenase in human renal microsomes. Drug Metab. Dispos., 2001, 29(2), 127-132.
219. Pike, M. G.; Martin, Y. N.; Mays, D. C.; Benson, L. M.; Naylor, S.; Lipsky, J. J. Roles of FMO and CYP450 in the metabolism in human liver microsomes of S-methyl-N,N-diethyldithiocarbamate, a disulfiram metabolite. Alcohol Clin. Exp. Res., 1999, 23(7), 1173-1179.
220. Erickson, D. A.; Mather, G.; Trager, W. F.; Levy, R. H.; Keirns, J. J. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab. Dispos., 1999, 27(12), 1488-1495.
221. Ward, B. A.; Gorski, J. C.; Jones, D. R.; Hall, S. D.; Flockhart, D. A.; Desta, Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther., 2003, 306(1), 287-300.
222. Tougou, K.; Gotou, H.; Ohno, Y.; Nakamura, A. Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica, 2004, 34(5), 449-461.
223. Pelkonen, O.; Rautio, A.; Raunio, H.; Pasanen, M. CYP2A6: a human coumarin 7-hydroxylase. Toxicology, 2000, 144(1-3), 139-147.
224. Hesse, L. M.; Venkatakrishnan, K.; von Moltke, L. L.; Shader, R. I.; Greenblatt, D. J. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab. Dispos., 2001, 29(2), 133-140.
225. Spracklin, D. K.; Hankins, D. C.; Fisher, J. M.; Thummel, K. E.; Kharasch, E. D. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J. Pharmacol. Exp. Ther., 1997, 281(1), 400-411.
226. Granvil, C. P.; Madan, A.; Sharkawi, M.; Parkinson, A.; Wainer, I. W. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of R- and S-ifosfamide in human liver microsomes. Drug Metab. Dispos., 1999, 27(4), 533-541.
227. Jeong, S.; Woo, M. M.; Flockhart, D. A.; Desta, Z. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro. Cancer Chemother. Pharmacol., 2009, [Epub ahead of printing].
228. Imaoka, S.; Enomoto, K.; Oda, Y.; Asada, A.; Fujimori, M.; Shimada, T.; Fujita, S.; Guengerich, F. P.; Funae, Y. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: Comparison of those with rat hepatic cytochrome P-450s. J. Pharmacol. Exp. Ther., 1990, 255(1385-1391.
229. Bargetzi, M. J.; Aoyama, T.; Gonzalez, F. J.; Meyer, U. A. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin. Pharmacol. Ther., 1989, 46(5), 521-527.
230. Lee, S. H.; Slattery, J. T. Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes. Drug Metab. Dispos., 1997, 25(12), 1354-1358.
231. Gainsborough, N.; Nelson, M. L.; Maskrey, V.; Swift, C. G.; Jackson, S. H. The pharmacokinetics and pharmacodynamics of medifoxamine after oral administration in healthy elderly volunteers. Eur. J. Clin. Pharmacol., 1994, 46(2), 163-166.
232. Kharasch, E. D.; Thummel, K. E. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology, 1993, 79(4), 795-807.
233. 4 receptor antagonist, in humans. Drug Metab. Dispos., 1997, 25(9), 1022-1031.
234. Wen, B.; Chen, Y.; Fitch, W. L. Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4. Drug Metab. Dispos., 2009, 37(7), 1557-1562.
235. Skaanild, M. T.; Friis, C. Is bupropion a more specific substrate for porcine CYP2E than chlorzoxazone and p-nitrophenol? Basic Clin. Pharmacol. Toxicol., 2007, 101(3), 159-162.
236. 14C]omeprazole in humans. Drug Metab. Dispos., 1989, 17(1), 69-76.
237. Bartoli, A.; Xiaodong, S.; Gatti, G.; Cipolla, G.; Marchiselli, R.; Perucca, E. The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. Ther. Drug Monit., 1996, 18(5), 586-591.
238. Kobayashi, K.; Nakajima, M.; Oshima, K.; Shimada, N.; Yokoi, T.; Chiba, K. Involvement of CYP2E1 as a low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab. Dispos., 1999, 27(8), 860-865.
239. Wojcikowski, J.; Pichard-Garcia, L.; Maurel, P.; Daniel, W. A. Contribution of human cytochrome P-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br. J. Pharmacol., 2003, 138(8), 1465-1474.
240. Bae, S. K.; Cao, S.; Seo, K. A.; Kim, H.; Kim, M. J.; Shon, J. H.; Liu, K. H.; Zhou, H. H.; Shin, J. G. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl] -3-methylbutyl}-N,Ndimethylamine) metabolites in human liver microsomes. Drug Metab. Dispos., 2008, 36(8), 1679-1688.
241. Guitton, J.; Buronfosse, T.; Desage, M.; Flinois, J. P.; Perdrix, J. P.; Brazier, J. L.; Beaune, P. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br. J. Anaesth., 1998, 80(6), 788-795.
242. Court, M. H.; Duan, S. X.; Hesse, L. M.; Venkatakrishnan, K.; Greenblatt, D. J. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology, 2001, 94(1), 110-119.
243. Crewe, H. K.; Notley, L. M.; Wunsch, R. M.; Lennard, M. S.; Gillam, E. M. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos., 2002, 30(8), 869-874.
244. Zhang, Q. Y.; Dunbar, D.; Kaminsky, L. Human cytochrome P450 metabolism of retinals to retinoic acids. Drug Metab. Dispos., 2000, 28(3), 292-297.
245. Jacobson, P. A.; Green, K.; Birnbaum, A.; Remmel, R. P. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother. Pharmacol., 2002, 49(6), 461-467.
246. Kiang, T. K.; Ho, P. C.; Anari, M. R.; Tong, V.; Abbott, F. S.; Chang, T. K. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol. Sci., 2006, 94(2), 261-271.
247. 5 in the reductive metabolism of 3′-azido-3′- deoxythymidine (AZT) to 3′-amino-3′-deoxythymidine. Biochem. Pharmacol., 1998, 55(6), 757-766.
248. Ghanbari, F.; Rowland-Yeo, K.; Bloomer, J. C.; Clarke, S. E.; Lennard, M. S.; Tucker, G. T.; Rostami-Hodjegan, A. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr. Drug Metab., 2006, 7(3), 315-334.
249. Zhou, S.; Chan, E.; Lim, L. Y.; Boelsterli, U. A.; Li, S. C.; Wang, J.; Zhang, Q.; Huang, M.; Xu, A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug Metab., 2004, 5(5), 415-442.
250. Zhou, S. F.; Xue, C. C.; Yu, X. Q.; Li, C.; Wang, G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit., 2007, 29(6), 687-710.
251. Zhou, Z. W.; Zhou, S. F. Application of mechanism-based CYP inhibition for predicting drug-drug interactions. Expert Opin. Drug Metab. Toxicol., 2009, 5(6), 579-605.
252. Pitarque, M.; von Richter, O.; Rodriguez-Antona, C.; Wang, J.; Oscarson, M.; Ingelman-Sundberg, M. A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. Hum. Mutat., 2004, 23(3), 258-266.
253. Ariyoshi, N.; Takahashi, Y.; Miyamoto, M.; Umetsu, Y.; Daigo, S.; Tateishi, T.; Kobayashi, S.; Mizorogi, Y.; Loriot, M. A.; Stucker, I.; Beaune, P.; Kinoshita, M.; Kamataki, T. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics, 2000, 10(8), 687-693.
254. Nakajima, M.; Fukami, T.; Yamanaka, H.; Higashi, E.; Sakai, H.; Yoshida, R.; Kwon, J. T.; McLeod, H. L.; Yokoi, T. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin. Pharmacol. Ther., 2006, 80(3), 282-297.
255. Mwenifumbo, J. C.; Lessov-Schlaggar, C. N.; Zhou, Q.; Krasnow, R. E.; Swan, G. E.; Benowitz, N. L.; Tyndale, R. F. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin. Pharmacol. Ther., 2008, 83(1), 115-121.
256. Nakajima, M.; Yoshida, R.; Fukami, T.; McLeod, H. L.; Yokoi, T. Novel human CYP2A6 alleles confound gene deletion analysis. FEBS Lett., 2004, 569(1-3), 75-81.
257. Mwenifumbo, J. C.; Al Koudsi, N.; Ho, M. K.; Zhou, Q.; Hoffmann, E. B.; Sellers, E. M.; Tyndale, R. F. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum. Mutat., 2008, 29(5), 679-688.
258. Ariyoshi, N.; Sekine, H.; Saito, K.; Kamataki, T. Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese. Pharmacogenetics, 2002, 12(6), 501-504.
259. Ariyoshi, N.; Sekine, H.; Nakayama, K.; Saito, K.; Miyamoto, A.; Kamataki, T. Identification of deletion-junction site of CYP2A6*4B allele lacking entire coding region of CYP2A6 in Japanese. Pharmacogenetics, 2004, 14(10), 701-705.
260. Ho, M. K.; Mwenifumbo, J. C.; Zhao, B.; Gillam, E. M.; Tyndale, R. F. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet. Genomics, 2008, 18(1), 67-75.
261. Al Koudsi, N.; Ahluwalia, J. S.; Lin, S. K.; Sellers, E. M.; Tyndale, R. F. A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. Pharmacogenomics J., 2009, 9(4), 274-282.
262. Saito, S.; Iida, A.; Sekine, A.; Kawauchi, S.; Higuchi, S.; Ogawa, C.; Nakamura, Y. Catalog of 680 variations among eight cytochrome P450 (CYP) genes, nine esterase genes, and two other genes in the Japanese population. J. Hum. Genet., 2003, 48(5), 249-270.
263. Solus, J. F.; Arietta, B. J.; Harris, J. R.; Sexton, D. P.; Steward, J. Q.; McMunn, C.; Ihrie, P.; Mehall, J. M.; Edwards, T. L.; Dawson, E. P. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics, 2004, 5(7), 895-931.